{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurofibromatosis+Type+1&page=2",
    "query": {
      "condition": "Neurofibromatosis Type 1",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurofibromatosis+Type+1&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T22:33:40.808Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05377008",
      "title": "Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neurocognitive Deficit",
        "Mental Health Impairment",
        "Neurofibromatosis 1"
      ],
      "interventions": [
        {
          "name": "OPTIMAL-SSI",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "6 Years to 16 Years"
      },
      "enrollment_count": 38,
      "start_date": "2022-05-13",
      "completion_date": "2023-05-05",
      "has_results": false,
      "last_update_posted_date": "2023-09-22",
      "last_synced_at": "2026-05-21T22:33:40.808Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05377008"
    },
    {
      "nct_id": "NCT00508235",
      "title": "Quality of Friendships in Children With Neurofibromatosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neurofibromatosis"
      ],
      "interventions": [
        {
          "name": "Questionnaire",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "8 Years to 18 Years"
      },
      "enrollment_count": 61,
      "start_date": "2004-12",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2012-08-01",
      "last_synced_at": "2026-05-21T22:33:40.808Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00508235"
    },
    {
      "nct_id": "NCT01968590",
      "title": "Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurofibromatosis Type 1 (NF1)"
      ],
      "interventions": [
        {
          "name": "Cholecalciferol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "25 Years to 40 Years"
      },
      "enrollment_count": 26,
      "start_date": "2017-08-16",
      "completion_date": "2022-01-01",
      "has_results": false,
      "last_update_posted_date": "2022-05-25",
      "last_synced_at": "2026-05-21T22:33:40.808Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01968590"
    },
    {
      "nct_id": "NCT01633008",
      "title": "Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Neurofibromatosis"
      ],
      "interventions": [
        {
          "name": "ACT Workshop",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "12 Years to 99 Years"
      },
      "enrollment_count": 28,
      "start_date": "2012-06-15",
      "completion_date": "2017-01-10",
      "has_results": false,
      "last_update_posted_date": "2019-09-30",
      "last_synced_at": "2026-05-21T22:33:40.808Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01633008"
    },
    {
      "nct_id": "NCT01275586",
      "title": "Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Neurofibromatosis",
        "NF1",
        "Neurofibromas"
      ],
      "interventions": [
        {
          "name": "Tasigna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2011-01",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2017-04-12",
      "last_synced_at": "2026-05-21T22:33:40.808Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01275586"
    },
    {
      "nct_id": "NCT01089101",
      "title": "Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Low Grade Glioma",
        "Recurrent Childhood Pilocytic Astrocytoma",
        "Recurrent Neurofibromatosis Type 1",
        "Recurrent Visual Pathway Glioma",
        "Refractory Neurofibromatosis Type 1",
        "Refractory Visual Pathway Glioma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Selumetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 217,
      "start_date": "2010-07-07",
      "completion_date": "2027-03-18",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-21T22:33:40.808Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01089101"
    },
    {
      "nct_id": "NCT03095248",
      "title": "Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurofibromatosis 2",
        "Vestibular Schwannoma",
        "Meningioma",
        "Ependymoma",
        "Glioma"
      ],
      "interventions": [
        {
          "name": "Selumetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "3 Years to 45 Years"
      },
      "enrollment_count": 10,
      "start_date": "2017-05-08",
      "completion_date": "2024-05-21",
      "has_results": true,
      "last_update_posted_date": "2025-04-22",
      "last_synced_at": "2026-05-21T22:33:40.808Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03095248"
    },
    {
      "nct_id": "NCT05677594",
      "title": "Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neurofibromatosis 1",
        "Malignant Peripheral Nerve Sheath Tumor (MPNST) of Soft Tissue (Diagnosis)",
        "Atypical Neurofibroma"
      ],
      "interventions": [
        {
          "name": "Whole Body Magnetic Resonance Imaging",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2021-07-01",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-05-21T22:33:40.808Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05677594"
    },
    {
      "nct_id": "NCT04166409",
      "title": "A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Low Grade Astrocytoma",
        "Low Grade Glioma",
        "Metastatic Low Grade Astrocytoma",
        "Metastatic Low Grade Glioma",
        "WHO Grade 1 Glioma",
        "WHO Grade 2 Glioma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Selumetinib Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 170,
      "start_date": "2020-01-31",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-05-21T22:33:40.808Z",
      "location_count": 124,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04166409"
    },
    {
      "nct_id": "NCT05238909",
      "title": "Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neurofibromatosis 1",
        "NF1",
        "Neurofibromatosis Type 1"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 200,
      "start_date": "2022-03-04",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-05-21T22:33:40.808Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05238909"
    }
  ]
}